Loading…
Dividends declared (per SOCE filings): FY2023 0 · FY2024 87 — 2-yr total 87
Shotapharm LLC is a Tbilisi-based pharmaceutical company operating in the Gldani / Tbilisi Technology Park free industrial zone, engaged in pharmaceutical manufacturing and distribution alongside other Turkish-linked pharma investments in Georgia.
| Ratio | 2023 | 2024 |
|---|---|---|
| Margins | ||
| Gross Margin | 38.0% | 49.6% |
| EBITDA Margin | 36.9% | 47.9% |
| EBITDAR | 46,892 | 156,914 |
| EBITDAR Margin | 36.9% | 47.9% |
| EBIT Margin | 36.9% | 47.9% |
| Net Profit Margin | 36.9% | 47.9% |
| Operating Expense % of Sales | 1.2% | 1.7% |
| Returns | ||
| Return on Assets (ROA) | 36.8% | 45.2% |
| Return on Equity (ROE) | 97.5% | 74.0% |
| ROIC [EBIT / Invested Capital] | 100.5% | 77.2% |
| Leverage & debt balances | ||
| Debt-to-Assets | 0.0% | 0.0% |
| Debt-to-Equity | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.00x | 0.00x |
| Equity-to-Assets | 37.8% | 61.0% |
| Net Debt | -1,463 | -8,614 |
| Cash & Equivalents | 1,463 | 8,614 |
| Total Debt | N/A | N/A |
| Liquidity & working capital | ||
| Current Ratio | 1.61x | 2.56x |
| Quick Ratio | 1.61x | 2.51x |
| Cash Ratio | 0.02x | 0.06x |
| Total Current Assets | 127,327 | 347,147 |
| Total Current Liabilities | 79,222 | 135,425 |
| Inventory | N/A | 7,354 |
| Trade Receivables | 125,864 | 331,449 |
| Trade Payables | 79,222 | 135,425 |
| Net Working Capital | 48,105 | 211,722 |
| Net Working Capital % of Revenue | 37.8% | 64.7% |
| Trade Working Capital | 46,642 | 203,378 |
| Trade Working Capital % of Revenue | 36.7% | 62.1% |
| Change in Trade Working Capital | N/A | 156,736 |
| Turnover & efficiency | ||
| Inventory Turnover | N/A | 22.43x |
| Days Inventory Outstanding (DIO) | N/A | 16.3 |
| Receivables Turnover | 1.01x | 0.99x |
| Days Sales Outstanding (DSO) | 361.1 | 369.5 |
| Payables Turnover | 1.00x | 1.22x |
| Days Payable Outstanding (DPO) | 366.8 | 299.7 |
| Cash Conversion Cycle | -5.7 days | 86.1 days |
| Asset Turnover | 1.00x | 0.94x |
| Cash flow & dividends | ||
| Operating Cash Flow | 1,401 | -973 |
| Free Cash Flow (OCF − Capex proxy) | 1,401 | -973 |
| Cash Conversion (OCF / EBITDA) | 3.0% | -0.6% |
| Dividends Declared | 0 | 87 |
| Dividend Payout Ratio | 0.0% | 0.1% |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →